U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H8O2
Molecular Weight 124.1372
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEQUINOL

SMILES

COC1=CC=C(O)C=C1

InChI

InChIKey=NWVVVBRKAWDGAB-UHFFFAOYSA-N
InChI=1S/C7H8O2/c1-9-7-4-2-6(8)3-5-7/h2-5,8H,1H3

HIDE SMILES / InChI

Molecular Formula C7H8O2
Molecular Weight 124.1372
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Mequinol (mequinol is 4-hydroxyanisole) is an active ingredient in topical drugs used for skin depigmentation. The mechanism of action of mequinol is unknown. Although mequinol is a substrate for the enzyme tyrosinase and acts as a competitive inhibitor of the formation of melanin precursors, the clinical significance of these findings is unknown.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SOLAGE

Approved Use

Mequinol is a depigmenting agent. The mechanism of depigmenting effects of mequinol remain unclear; speculations include oxidation by tyrosinase to cytotoxic products in melanocytes, a direct/selective toxic effect on melanocytes, or inhibition of melanin formation

Launch Date

9.4478402E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.92 ng/mL
16 μL 1 times / day steady-state, topical
dose: 16 μL
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
MEQUINOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.43 ng × h/mL
16 μL 1 times / day steady-state, topical
dose: 16 μL
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
MEQUINOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5 h
16 μL 1 times / day steady-state, topical
dose: 16 μL
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
MEQUINOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 % 1 times / day steady, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: steady
Dose: 2 %, 1 times / day
Co-administed with::
tretinoin(0.0001)
Sources:
healthy, 55.8 years
n = 159
Health Status: healthy
Condition: solar lentigines
Age Group: 55.8 years
Sex: M+F
Population Size: 159
Sources:
Disc. AE: Dermal and epidermal conditions NEC, Skin and subcutaneous tissue disorders...
Other AEs: Hematuria...
AEs leading to
discontinuation/dose reduction:
Dermal and epidermal conditions NEC (3.5%)
Skin and subcutaneous tissue disorders (5.8%)
Other AEs:
Hematuria (3.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hematuria 3.5%
2 % 1 times / day steady, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: steady
Dose: 2 %, 1 times / day
Co-administed with::
tretinoin(0.0001)
Sources:
healthy, 55.8 years
n = 159
Health Status: healthy
Condition: solar lentigines
Age Group: 55.8 years
Sex: M+F
Population Size: 159
Sources:
Dermal and epidermal conditions NEC 3.5%
Disc. AE
2 % 1 times / day steady, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: steady
Dose: 2 %, 1 times / day
Co-administed with::
tretinoin(0.0001)
Sources:
healthy, 55.8 years
n = 159
Health Status: healthy
Condition: solar lentigines
Age Group: 55.8 years
Sex: M+F
Population Size: 159
Sources:
Skin and subcutaneous tissue disorders 5.8%
Disc. AE
2 % 1 times / day steady, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: steady
Dose: 2 %, 1 times / day
Co-administed with::
tretinoin(0.0001)
Sources:
healthy, 55.8 years
n = 159
Health Status: healthy
Condition: solar lentigines
Age Group: 55.8 years
Sex: M+F
Population Size: 159
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Catalytic effect of soil colloids on the reaction between CrVI and p-methoxyphenol.
2001
Degradation of isoxaben in soils and an aqueous system.
2001 Nov
Speciation of gas-phase and fine particle emissions from burning of foliar fuels.
2002 Jun 1
Enhancement of the depigmenting effect of hydroquinone and 4-hydroxyanisole by all-trans-retinoic acid (tretinoin): the impairment of glutathione-dependent cytoprotection?
2003
Anise oil as para-methoxyamphetamine (PMA) precursor.
2003 Apr 23
A combination of ultrasound and oxidative enzyme: sono-biodegradation of substituted phenols.
2003 Jul
Antinociceptive properties of chloromaleinimides and their sulphonyl derivatives.
2004 Apr
Effect of phenolic mediators and humic acid on cyprodinil transformation in presence of birnessite.
2004 Jun
On the etiology of contact/occupational vitiligo.
2004 Jun
Purification and characterization of tyrosinase from gill tissue of Portabella mushrooms.
2004 Mar
Structural close-related aromatic compounds have different effects on laccase activity and on lcc gene expression in the ligninolytic fungus Trametes sp. I-62.
2004 Oct
Site-specific H/D exchange of p-methoxyphenol studied by resonant two-photon ionization and mass-analyzed threshold ionization spectroscopy.
2005 Oct 27
The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups.
2006 Sep
Separation of molecular tracers sorbed onto atmospheric particulate matter by flash chromatography.
2007 Mar
A novel melanin inhibitor: hydroperoxy traxastane-type triterpene from flowers of Arnica montana.
2007 May
Urinary methoxyphenol biomarkers and woodsmoke exposure: comparisons in rural Guatemala with personal CO and kitchen CO, levoglucosan, and PM2.5.
2007 May 15
Subcellular localization and cytoplasmic complex status of endogenous Keap1.
2007 Oct
Suppression of interleukin-2 gene expression by isoeugenol is mediated through down-regulation of NF-AT and NF-kappaB.
2007 Sep
Electrochemical oxidation characteristics of p-substituted phenols using a boron-doped diamond electrode.
2007 Sep 15
Laser flash photolysis study of the triplet reactivity of beta-lapachones.
2008 Apr
Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature.
2008 Feb
Efficient synthesis and properties of novel near-infrared electrochromic anthraquinone imides.
2008 Feb 21
Metabolic bioactivation and toxicity of ethyl 4-hydroxybenzoate in human SK-MEL-28 melanoma cells.
2008 May
The mechanism of the phosphoramidite synthesis of polynucleotides.
2008 Sep 21
Topical treatment of melasma.
2009
Peroxidase-mediated degradation of perfluorooctanoic acid.
2009 Feb
Urinary levoglucosan as a biomarker of wood smoke exposure: observations in a mouse model and in children.
2009 Jan
Production of o-diphenols by immobilized mushroom tyrosinase.
2009 Jan 15
Increase in the levels of chaperone proteins by exposure to beta-estradiol, bisphenol A and 4-methoxyphenol in human cells transfected with estrogen receptor alpha cDNA.
2009 Jun
Tris{2-meth-oxy-6-[(4-methyl-phen-yl)iminiometh-yl]phenolate-κO,O'}tris-(thio-cyanato-κN)europium(III).
2009 Nov 21
Development and evaluation of kinetic spectrophotometric assays for horseradish peroxidase by catalytic coupling of paraphenylenediamine and mequinol.
2009 Oct
(E)-2-[(4-Ethoxy-phen-yl)imino-meth-yl]-4-methoxy-phenol.
2009 Oct 10
6,6'-Dimeth-oxy-2,2'-[(E,E')-(4-chloro-m-phenyl-ene)bis-(nitrilo-methyl-idyne)]diphenol.
2009 Sep 30
Antioxidant activity of colored rice bran obtained at different milling yields.
2010
Radical-scavenging activity and cytotoxicity of p-methoxyphenol and p-cresol dimers.
2010 Feb 26
Heterogeneous reaction of gaseous ozone with aqueous iodide in the presence of aqueous organic species.
2010 May 20
Structure and vibrational frequencies of 6,7-dimethoxy-1,4-dihydro-1,3-quinoxalinedione based on density functional theory calculations: The role of pi-electron conjugation and back-donation.
2010 Sep 15
Patents

Sample Use Guides

Apply Solagé to the solar lentigines using the applicator tip while avoiding application to the surrounding skin. Use twice daily, morning and evening at least 8 hours apart, or as directed by a physician. Patients should not shower or bathe the treatment areas for at least 6 hours after application of Solagé. Special caution should be taken when applying Solagé to avoid the eyes, mouth, paranasal creases, and mucous membranes.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 16 15:53:14 UTC 2022
Edited
by admin
on Fri Dec 16 15:53:14 UTC 2022
Record UNII
6HT8U7K3AM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEQUINOL
HSDB   INN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
SOLAGE COMPONENT MEQUINOL
Common Name English
4-Methoxyphenol
Systematic Name English
Mequinol [WHO-DD]
Common Name English
MEQUINOL [ORANGE BOOK]
Common Name English
MEQUINOL COMPONENT OF SOLAGE
Common Name English
MEQUINOL [MART.]
Common Name English
P-HYDROXYANISOLE
INCI  
INCI  
Official Name English
NSC-4960
Code English
MEQUINOL [USAN]
Common Name English
PHENOL, 4-METHOXY-
Systematic Name English
BMS-181158
Code English
P-HYDROXYANISOLE [INCI]
Common Name English
MEQUINOL [HSDB]
Common Name English
mequinol [INN]
Common Name English
MEQUINOL [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78284
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
NDF-RT N0000175851
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
WHO-ATC D11AX06
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
NDF-RT N0000175855
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
NDF-RT N0000175850
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
CFR 21 CFR 176.170
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
WHO-VATC QD11AX06
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
Code System Code Type Description
DRUG BANK
DB09516
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
CAS
150-76-5
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
ChEMBL
CHEMBL544
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
HSDB
4258
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
RXCUI
15080
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY RxNorm
FDA UNII
6HT8U7K3AM
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
DAILYMED
6HT8U7K3AM
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
INN
1542
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
IUPHAR
6827
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
ECHA (EC/EINECS)
205-769-8
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
EVMPD
SUB08764MIG
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
EPA CompTox
DTXSID4020828
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
USAN
LL-42
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
NCI_THESAURUS
C47604
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
DRUG CENTRAL
4221
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
MESH
C009760
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
NSC
4960
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
PUBCHEM
9015
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
WIKIPEDIA
MEQUINOL
Created by admin on Fri Dec 16 15:53:14 UTC 2022 , Edited by admin on Fri Dec 16 15:53:14 UTC 2022
PRIMARY
Related Record Type Details
ACTIVE MOIETY